Open Access Peer-reviewed Research Article

Optimizing Pre-operative Clinical Staging in Resectable Non-Small Cell Lung Cancer: A Retrospective Cohort Study

Article Sidebar

Kaplan Meir survival estimate
Download PDF
Submitted   Jan 28, 2025
Published   May 13, 2025
Issue    Vol 7 (2025)
DOI   10.25082/CCR.2025.01.002

Views

0

Downloads

0

Citations

PlumX Metrics

Main Article Content

Evangeline Samuel corresponding author
[1] Department of Medical Oncology, Latrobe Regional Health, Victoria, Australia; [2] School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
C. Thomas
Department of Respiratory Medicine, Alfred Health, Melbourne, Australia
C. Thompson
Department of Radiology, Alfred Health, Melbourne, Australia
E. Paul
[1] School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; [2] Monash University, Melbourne, Australia
M. Cherk
[1] Department of Nuclear Medicine & PET, Alfred Hospital, Melbourne, Australia; [2] Monash University, Melbourne, Australia

Abstract

Background: Accurate pre-operative clinical staging is vital for guiding treatment decisions in resectable non-small cell lung cancer (NSCLC). Discrepancies between clinical and pathological stages raise concerns about treatment appropriateness.
Objective: The objective of the study is to determine the accuracy of the pre-operative clinical stage (cTN) with the post-operative pathological stage (pTN), examine factors predictive of inaccurate staging and explore the impacts on survival.
Patient and Methods: This retrospective cohort study in Melbourne, Australia, analyzed stage I-IIIA NSCLC patients between 2011-2020. Primary exposures were pre-operative clinical stage (CT, PET, nodal evaluation) and post-operative pathological stage. The primary outcome was stage concordance between clinical and pathological stages of resected NSCLC. Various patient, tumour and surgical characteristics and quality of care metrics were collected from medical records. Logistic regression and COX proportional hazards regression assessed factors influencing staging concordance and survival.
Results: Among 221 patients, 58% showed overall staging concordance. Discordance (42%) frequently led to upstaging (23.9%) or downstaging (17.2%) at pathology. Nodal stage concordance was influenced by female sex, SUV max, histology, and timing between CT and surgery. Nodal stage discordance independently correlated with higher mortality risk (p = 0.002, HR 2.37).
Conclusions: The results of our study indicate inconsistencies between clinical methods of staging and pathological stages of NSCLC. Further optimization of clinical staging is essential for patients to receive guideline-concordant treatment. Pathological upstaging provides a significant safety risk and can result in adverse survival outcomes.

Keywords
stage concordance, stage discordance, stage migration, NSCLC, quality indicators, risk prediction

Article Details

How to Cite
Samuel, E., Thomas, C., Thompson, C., Paul, E., Cherk, M., Ellis, S., Siemienowicz, M., Tissera, S., Samankula, U., Scholz, S., Zhang, L., Grewal, J., Cox, J., Yu, C., Adabi, G., Keating, D., Taverner, J., Gooi, J., Wayne, S., Zalcberg, J., & Stirling, R. G. (2025). Optimizing Pre-operative Clinical Staging in Resectable Non-Small Cell Lung Cancer: A Retrospective Cohort Study. Current Cancer Reports, 7, 269-279. https://doi.org/10.25082/CCR.2025.01.002
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

References

  1. World Health Organization. (n.d.). Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer
  2. American Cancer Society. (n.d.). Survival Rates for Lung Cancer. https://www.cancer.org
  3. Paesmans M. Prognostic and predictive factors for lung cancer. Breathe. 2012, 9(2): 112-121. https://doi.org/10.1183/20734735.006911
  4. Detterbeck FC, Boffa DJ, Kim AW, et al. The Eighth Edition Lung Cancer Stage Classification. Chest. 2017, 151(1): 193-203. https://doi.org/10.1016/j.chest.2016.10.010
  5. Howington JA, Blum MG, Chang AC, et al. Treatment of Stage I and II Non-small Cell Lung Cancer. Chest. 2013, 143(5): e278S-e313S. https://doi.org/10.1378/chest.12-2359
  6. Rami-Porta R, Call S, Dooms C, et al. Lung cancer staging: a concise update. European Respiratory Journal. 2018, 51(5): 1800190. https://doi.org/10.1183/13993003.00190-2018
  7. De Leyn P, Dooms C, Kuzdzal J, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. European Journal of Cardio-Thoracic Surgery. 2014, 45(5): 787-798. https://doi.org/10.1093/ejcts/ezu028
  8. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for Staging Non-small Cell Lung Cancer. Chest. 2013, 143(5): e211S-e250S. https://doi.org/10.1378/chest.12-2355
  9. Koukis I, Gkiozos I, Ntanos I, et al. Clinical and surgical-pathological staging in early non-small cell lung cancer. Oncology Reviews. 2013, 7(1): 7. https://doi.org/10.4081/oncol.2013.e7
  10. Stokes SM, Massarweh NN, Stringham JR, et al. Clinical-Pathologic Correlation and Guideline Concordance in Resectable Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery. 2019, 108(3): 837-844. https://doi.org/10.1016/j.athoracsur.2019.03.062
  11. Dyas AR, King RW, Ghanim AF, et al. Clinical Misstagings and Risk Factors of Occult Nodal Disease in Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery. 2018, 106(5): 1492-1498. https://doi.org/10.1016/j.athoracsur.2018.05.045
  12. Kanzaki R, Higashiyama M, Fujiwara A, et al. Occult mediastinal lymph node metastasis in NSCLC patients diagnosed as clinical N0-1 by preoperative integrated FDG-PET/CT and CT: Risk factors, pattern, and histopathological study. Lung Cancer. 2011, 71(3): 333-337. https://doi.org/10.1016/j.lungcan.2010.06.008
  13. Al-Sarraf N, Gately K, Lucey J, et al. Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases. European Journal of Cardio-Thoracic Surgery. 2008, 34(4): 892-897. https://doi.org/10.1016/j.ejcts.2008.07.023
  14. Kim DH, Song BI, Hong CM, et al. Metabolic parameters using 18F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 2014, 41(11): 2051-2057. https://doi.org/10.1007/s00259-014-2831-6
  15. Elm E von, Altman DG, Egger M, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007, 335(7624): 806-808. https://doi.org/10.1136/bmj.39335.541782.ad
  16. Australia Postcodes. (n.d.). Distance Between Postcodes. https://www.australiapostcodes.com/distance-between-postcodes
  17. Australian Government Department of Health. (n.d.). Modified Monash Model. https://www.health.gov.au
  18. Jakobsen E, Rasmussen T. The Danish Lung Cancer Registry. Clinical Epidemiology. 2016, Volume 8: 537-541. https://doi.org/10.2147/clep.s99458
  19. Stenger M, Jakobsen E, Wright G, et al. A comparison of outcomes and survival between Victoria and Denmark in lung cancer surgery: opportunities for international benchmarking. ANZ Journal of Surgery. 2021, 92(5): 1050-1055. https://doi.org/10.1111/ans.17302
  20. Solberg S, Nilssen Y, Terje Brustugun O, et al. Concordance between clinical and pathology TNM-staging in lung cancer. Lung Cancer. 2022, 171: 65-69. https://doi.org/10.1016/j.lungcan.2022.07.014
  21. Taylor O, Boardman G, Bentel J, et al. Discordance between clinical and pathologic staging and the timeliness of care of non‐small cell lung cancer patients diagnosed with operable tumors. Asia-Pacific Journal of Clinical Oncology. 2023, 19(6): 706-714. https://doi.org/10.1111/ajco.13934
  22. Verma S, Chan J, Chew C, et al. PET-SUV Max and Upstaging of Lung Cancer. Heart, Lung and Circulation. 2019, 28(3): 436-442. https://doi.org/10.1016/j.hlc.2017.12.011
  23. Liu J, Dong M, Sun X, et al. Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis. Patnaik S, ed. PLOS ONE. 2016, 11(1): e0146195. https://doi.org/10.1371/journal.pone.0146195
  24. Koksal D, Demirag F, Bayiz H, et al. The correlation of SUVmax with pathological characteristics of primary tumor and the value of Tumor/ Lymph node SUVmax ratio for predicting metastasis to lymph nodes in resected NSCLC patients. Journal of Cardiothoracic Surgery. 2013, 8(1). https://doi.org/10.1186/1749-8090-8-63
  25. Bissonnette JP, Sun A, Grills IS, et al. Non-small cell lung cancer stage migration as a function of wait times from diagnostic imaging: A pooled analysis from five international centres. Lung Cancer. 2021, 155: 136-143. https://doi.org/10.1016/j.lungcan.2021.03.017
  26. Cancer Council Victoria and Department of Health Victoria. Optimal care pathway for people with lung cancer, 2nd edn, Cancer Council Victoria, Melbourne, 2021. https://www.cancer.org.au
  27. Navani N, Nankivell M, Lawrence DR, et al. Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial. The Lancet Respiratory Medicine. 2015, 3(4): 282-289. https://doi.org/10.1016/s2213-2600(15)00029-6
  28. Tracey E, McCaughan B, Badgery-Parker T, et al. Survival of Australian lung cancer patients and the impact of distance from and attendance at a thoracic specialist centre: a data linkage study. Thorax. 2014, 70(2): 152-160. https://doi.org/10.1136/thoraxjnl-2014-205554